Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance–linked ABCG2 transporter

Multidrug resistance due to reduced drug accumulation is a phenomenon predominantly caused by the overexpression of members of the ATP-binding cassette (ABC) transporters, including ABCB1 (P-glycoprotein), ABCG2, and several ABCC family members [multidrug resistance–associated protein (MRP)]. We previously reported that a thiosemicarbazone derivative, NSC73306, is cytotoxic to carcinoma cells that overexpress functional P-glycoprotein, and it resensitizes these cells to chemotherapeutics. In this study, we investigated the effect of NSC73306 on cells overexpressing other ABC drug transporters, including ABCG2, MRP1, MRP4, and MRP5. Our findings showed that NSC73306 is not more toxic to cells that overexpress these transporters compared with their respective parental cells, and these transporters do not confer resistance to NSC73306 either. In spite of this, we observed that NSC73306 is a transport substrate for ABCG2 that can effectively inhibit ABCG2-mediated drug transport and reverse resistance to both mitoxantrone and topotecan in ABCG2-expressing cells. Interactions between NSC73306 and the ABCG2 drug-binding site(s) were confirmed by its stimulatory effect on ATPase activity (140–150 nmol/L concentration required for 50% stimulation) and by inhibition of [125I]iodoarylazidoprazosin photolabeling (50% inhibition at 250–400 nmol/L) of the substrate-binding site(s). Overall, NSC73306 seems to be a potent modulator of ABCG2 that does not interact with MRP1, MRP4, or MRP5. Collectively, these data suggest that NSC73306 can potentially be used, due to its dual mode of action, as an effective agent to overcome drug resistance by eliminating P-glycoprotein–overexpressing cells and by acting as a potent modulator that resensitizes ABCG2-expressing cancer cells to chemotherapeutics. [Mol Cancer Ther 2007;6(12):3287–96]

[1]  T. Litman,et al.  Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  S. Bates,et al.  ABCG2: determining its relevance in clinical drug resistance , 2007, Cancer and Metastasis Reviews.

[3]  Y. Sugimoto,et al.  Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants , 2003, International journal of cancer.

[4]  Hui Peng,et al.  Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. , 2007, Cancer research.

[5]  S. Bates,et al.  Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition , 2004, Cancer Research.

[6]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[7]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[8]  A. V. van Herwaarden,et al.  The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. , 2006, Trends in pharmacological sciences.

[9]  Suneet Shukla,et al.  The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. , 2006, Biochemistry.

[10]  J. Dimmock,et al.  Recent evaluations of thiosemicarbazones and semicarbazones and related compounds for antineoplastic and anticonvulsant activities. , 1993, Die Pharmazie.

[11]  S. Hladky,et al.  Modulatory effects of plant phenols on human multidrug‐resistance proteins 1, 4 and 5 (ABCC1, 4 and 5) , 2005, The FEBS journal.

[12]  J. Schellens,et al.  Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. , 1999, Cancer research.

[13]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[14]  T. Litman,et al.  Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2 , 2005, Journal of Cell Science.

[15]  S. Cole,et al.  Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. , 2006, Physiological reviews.

[16]  J. Wijnholds,et al.  Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. , 2002, Molecular pharmacology.

[17]  A. Fojo,et al.  Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. , 1990, The Journal of biological chemistry.

[18]  Yves Pommier,et al.  ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins , 2004, Journal of Pharmacology and Experimental Therapeutics.

[19]  Z. Sauna,et al.  Multidrug Resistance Protein 4 (ABCC4)-mediated ATP Hydrolysis , 2004, Journal of Biological Chemistry.

[20]  T. Ishikawa,et al.  Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. , 2004, Journal of experimental therapeutics & oncology.

[21]  M. Ishiyama,et al.  A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. , 1996, Biological & pharmaceutical bulletin.

[22]  S. Ambudkar,et al.  Relation Between the Turnover Number for Vinblastine Transport and for Vinblastine-stimulated ATP Hydrolysis by Human P-glycoprotein* , 1997, The Journal of Biological Chemistry.

[23]  S. Ambudkar.  Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. , 1998, Methods in enzymology.

[24]  K. Skubitz.  P-glycoprotein and multidrug resistance. , 1990, American journal of clinical pathology.

[25]  F. Baas,et al.  Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Callaghan,et al.  Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter , 2006, British journal of pharmacology.

[27]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[28]  D. Richardson,et al.  A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics , 2006, Proceedings of the National Academy of Sciences.

[29]  Scott E. Martin,et al.  Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. , 2006, Cancer research.

[30]  S. Bates,et al.  Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.

[31]  D. Gambino,et al.  The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes. , 2003, Mini reviews in medicinal chemistry.

[32]  S. Bates,et al.  Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. , 2003, Cancer research.

[33]  P. Borst,et al.  Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.

[34]  J. Wijnholds,et al.  Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. , 2000, Cancer research.

[35]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[36]  Suneet Shukla,et al.  Modulation of the function of the multidrug resistance–linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin , 2006, Molecular Cancer Therapeutics.

[37]  J. Schellens,et al.  Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. , 2000, Cancer research.

[38]  Z. Sauna,et al.  Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human P-glycoprotein (ABCB1). , 2002, Biochemistry.

[39]  M. Barrand,et al.  A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. , 1994, Journal of the National Cancer Institute.

[40]  T. Litman,et al.  A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). , 2001, Biochimica et biophysica acta.

[41]  Balázs Sarkadi,et al.  Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. , 2005, Biochimica et biophysica acta.

[42]  M. Gottesman,et al.  Overview: ABC Transporters and Human Disease , 2001, Journal of bioenergetics and biomembranes.

[43]  M. Dean,et al.  The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  T. Litman,et al.  Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. , 2001, Cancer research.

[45]  T. Tsuruo,et al.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.

[46]  S. Ambudkar,et al.  Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1). , 2002, Biochemistry.

[47]  G. Szakács,et al.  Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. , 2006, Physiological reviews.

[48]  J. Schellens,et al.  Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. , 2004, Clinical colorectal cancer.

[49]  D. Hipfner,et al.  Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. , 1994, Cancer research.